Trial Profile
A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2023
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary)
- Indications Myocardial infarction
- Focus Registrational; Therapeutic Use
- Acronyms ACCOAST; TADF
- Sponsors Eli Lilly and Company
- 28 Aug 2023 Results of an analysis comparing ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes using data from this trial presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 05 Mar 2019 Results assessing the effect of pre-treatment duration with prasugrel in Patients With Non-ST-Segment Elevation Myocardial Infarction published in the Journal of the American College of Cardiology
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association